Literature DB >> 18608205

Combination treatment of human umbilical cord matrix stem cell-based interferon-beta gene therapy and 5-fluorouracil significantly reduces growth of metastatic human breast cancer in SCID mouse lungs.

Raja Shekar Rachakatla1, Marla M Pyle, Rie Ayuzawa, Sarah M Edwards, Frank C Marini, Mark L Weiss, Masaaki Tamura, Deryl Troyer.   

Abstract

Umbilical cord matrix stem (UCMS) cells that were engineered to express interferon-beta (IFN-beta) were transplanted weekly for three weeks into MDA 231 breast cancer xenografts bearing SCID mice in combination with 5-fluorouracil (5-FU). The UCMS cells were found within lung tumors but not in other tissues. Although both treatments significantly reduced MDA 231 tumor area in the SCID mouse lungs, the combined treatment resulted in a greater reduction in tumor area than by either treatment used alone. These results indicate that a combination treatment of UCMS-IFN-beta cells and 5-FU is a potentially effective therapeutic procedure for breast cancer.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18608205     DOI: 10.1080/07357900701871134

Source DB:  PubMed          Journal:  Cancer Invest        ISSN: 0735-7907            Impact factor:   2.176


  21 in total

1.  Mesenchymal stem cells in preclinical cancer cytotherapy: a systematic review.

Authors:  Ioannis Christodoulou; Maria Goulielmaki; Marina Devetzi; Mihalis Panagiotidis; Georgios Koliakos; Vassilis Zoumpourlis
Journal:  Stem Cell Res Ther       Date:  2018-12-07       Impact factor: 6.832

Review 2.  Therapeutic potentials of mesenchymal stem cells derived from human umbilical cord.

Authors:  Cun-Gang Fan; Qing-jun Zhang; Jing-ru Zhou
Journal:  Stem Cell Rev Rep       Date:  2011-03       Impact factor: 5.739

3.  A self-contained enzyme activating prodrug cytotherapy for preclinical melanoma.

Authors:  Gwi-Moon Seo; Raja Shekar Rachakatla; Sivasai Balivada; Marla Pyle; Tej B Shrestha; Matthew T Basel; Carl Myers; Hongwang Wang; Masaaki Tamura; Stefan H Bossmann; Deryl L Troyer
Journal:  Mol Biol Rep       Date:  2011-05-13       Impact factor: 2.316

4.  Attenuation of mouse melanoma by A/C magnetic field after delivery of bi-magnetic nanoparticles by neural progenitor cells.

Authors:  Raja Shekar Rachakatla; Sivasai Balivada; Gwi-Moon Seo; Carl B Myers; Hongwang Wang; Thilani N Samarakoon; Raj Dani; Marla Pyle; Franklin O Kroh; Brandon Walker; Xiaoxuan Leaym; Olga B Koper; Viktor Chikan; Stefan H Bossmann; Masaaki Tamura; Deryl L Troyer
Journal:  ACS Nano       Date:  2010-11-08       Impact factor: 15.881

5.  Non-random tissue distribution of human naïve umbilical cord matrix stem cells.

Authors:  Dharmendra Kumar Maurya; Chiyo Doi; Marla Pyle; Raja Shekar Rachakatla; Duane Davis; Masaaki Tamura; Deryl Troyer
Journal:  World J Stem Cells       Date:  2011-04-26       Impact factor: 5.326

6.  Targeting of mesenchymal stem cells to ovarian tumors via an artificial receptor.

Authors:  Svetlana Komarova; Justin Roth; Ronald Alvarez; David T Curiel; Larisa Pereboeva
Journal:  J Ovarian Res       Date:  2010-05-25       Impact factor: 4.234

7.  Naïve human umbilical cord matrix derived stem cells significantly attenuate growth of human breast cancer cells in vitro and in vivo.

Authors:  Rie Ayuzawa; Chiyo Doi; Raja Shekar Rachakatla; Marla M Pyle; Dharmendra Kumar Maurya; Deryl Troyer; Masaaki Tamura
Journal:  Cancer Lett       Date:  2009-03-13       Impact factor: 8.679

8.  Translational Approaches towards Cancer Gene Therapy: Hurdles and Hopes.

Authors:  Jaleh Barar; Yadollah Omidi
Journal:  Bioimpacts       Date:  2012-09-22

9.  Naïve rat umbilical cord matrix stem cells significantly attenuate mammary tumor growth through modulation of endogenous immune responses.

Authors:  Atsushi Kawabata; Naomi Ohta; Garret Seiler; Marla M Pyle; Susumu Ishiguro; Yong Qing Zhang; Kevin G Becker; Deryl Troyer; Masaaki Tamura
Journal:  Cytotherapy       Date:  2013-03-07       Impact factor: 5.414

10.  Targeted Gene Therapy of Cancer: Second Amendment toward Holistic Therapy.

Authors:  Jaleh Barar; Yadollah Omidi
Journal:  Bioimpacts       Date:  2013-02-07
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.